Developing countries will pay less for COVID-19 drug – Gilead reveals | – Nairametrics

After weeks of debate of how Topline Gilead Sciences would develop pricing that balances social responsibility with its profits, the company has announced the pricing plan for Remdesivir, its coronav… [read more]

Leave a Reply

Your email address will not be published. Required fields are marked *